3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
10
Colorectal Cancer Metastatic
6
Neoplasm Metastasis
5
Lymphoma, Non-Hodgkin
5
Colorectal Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Burkitt Lymphoma
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Testicular Neoplasms
2
Sarcoma
2
Penile Neoplasms
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Interventions
Gemcitabine
205
130-nm albumin-bound paclitaxel
84
Albumin-Bound Paclitaxel
57
pembrolizumab
43
Fluorouracil
41
Leucovorin
34
Oxaliplatin
33
Capecitabine
25
Nivolumab
22
Irinotecan
19
Bevacizumab
17
Paclitaxel
16
Cyclophosphamide
15
Cetuximab
15
Taxes
13
Erlotinib Hydrochloride
13
Drug Therapy
13
Carboplatin
12
irinotecan sucrosofate
11
Injections
10
Cisplatin
9
fludarabine
8
ALT-803
8
spartalizumab
7
olaparib
7
avelumab
7
Pemetrexed
7
Docetaxel
7
ruxolitinib
6
TH 302
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Pancreatic Neoplasms
×
aflibercept
×
Clear all
NCT00574275
2016-06-07
VANILLA
Sanofi
Phase 3
Terminated
546 enrolled
14 charts